StartKLBF • IDX
add
Kalbe Farma Tbk PT
Seneste lukkekurs
1.390,00 Rp
Dagsinterval
1.360,00 Rp - 1.430,00 Rp
Årsinterval
985,00 Rp - 1.795,00 Rp
Markedsværdi
66,09 bio. IDR
Gns. volumen
47,68 mio.
P/E-værdi
19,30
Udbytteprocent
2,20 %
Primær børs
IDX
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
| (IDR) | mar. 2025info | År til år-ændring |
|---|---|---|
Indtægt | 8,85 bio. | 5,77 % |
Driftsudgifter | 2,24 bio. | 9,58 % |
Nettoindtægt | 1,08 bio. | 12,45 % |
Overskudsgrad | 12,17 | 6,29 % |
Earnings per share | 23,57 | 13,86 % |
EBITDA | 1,57 bio. | 11,60 % |
Effektiv afgiftssats | 22,83 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
| (IDR) | mar. 2025info | År til år-ændring |
|---|---|---|
Kontanter og korttidsinvesteringer | 4,69 bio. | 10,74 % |
Samlede aktiver | 30,58 bio. | 5,59 % |
Samlede passiver | 5,22 bio. | 7,63 % |
Samlet egenkapital | 25,36 bio. | — |
Shares outstanding | 45,65 mia. | — |
Kurs/indre værdi | 2,70 | — |
Afkast af aktiver | 11,54 % | — |
Afkast af kapital | 13,57 % | — |
Pengestrøm
Nettoændring i likviditet
| (IDR) | mar. 2025info | År til år-ændring |
|---|---|---|
Nettoindtægt | 1,08 bio. | 12,45 % |
Pengestrøm fra drift | 344,56 mia. | -71,44 % |
Pengestrøm fra investering | -118,66 mia. | 61,24 % |
Pengestrøm fra finansiering | -423,13 mia. | -791,88 % |
Nettoændring i likviditet | -180,46 mia. | -121,28 % |
Fri pengestrøm | -102,67 mia. | -114,36 % |
Om
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise.
The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, distribution arm that reaches over 1 million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient.
Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar.
Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
Grundlagt
10. sep. 1966
Website
Ansatte
12.841
